Zoliflodacin is a novel antibiotic under development for the treatment of uncomplicated urogenital gonorrhea, a sexually transmitted infection caused by Neisseria gonorrhoeae. It is particularly valuable as it targets strains of the bacteria that have developed resistance to other antibiotics, such as cephalosporins. This makes it a critical option in addressing the growing challenge of antimicrobial resistance in gonorrhea treatment. Zoliflodacin works by inhibiting the bacterial DNA gyrase, an enzyme essential for DNA replication, thereby stopping the growth and spread of the bacteria. Its oral administration offers a convenient and effective treatment option, reducing the need for injectable antibiotics. Ongoing clinical trials and research are exploring its efficacy and potential use in treating other bacterial infections.